Information Provided By: 
Fly News Breaks for May 3, 2018
ESPR
May 3, 2018 | 15:12 EDT
After speaking with Esperion management and a key opinion leader consultant, Cowen analyst Chris Shibutani said he believes that investor concerns regarding the safety profile of Esperion's bempedoic acid, in particular stemming from the numerical difference reported in CV-related deaths in the "Study 1" readout, are overdone. The analyst, who sees the pullback presenting a buying opportunity, keeps an Outperform rating and $95 price target on Esperion shares.
News For ESPR From the Last 2 Days
There are no results for your query ESPR
